ArticleCureus2026
Topical Steroid and Fairness Cream Abuse in Facial Dermatoses: A Cross-Sectional Study at a Tertiary Care Center in Western Uttar Pradesh.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAbuse of topical corticosteroids (TCS) and "fairness creams" on the face has become a significant dermatological problem in India, leading to a spectrum of adverse effects known as topical steroid-damaged/dependent face (TSDF). This study aims to assess the demographic profile of patients with facial TCS misuse, evaluate their perceptions and awareness regarding steroid use, and document the clinical adverse effects associated with misuse.
methodsA prospective, questionnaire-based, observational cross-sectional study was conducted over two months (July-August 2025) in the Department of Dermatology, Government Institute of Medical Sciences (GIMS), Western Uttar Pradesh. Ninety-six consecutive patients with a clinical diagnosis of TSDF were enrolled. Data regarding demographics, indications for use, source of recommendation, type and potency of steroids, duration of use, and cutaneous adverse effects were recorded in a preformed questionnaire and analyzed using IBM SPSS Statistics for Windows, Version 28.0 (Released 2021; IBM Corp., Armonk, NY, USA).
resultsOut of the 96 patients, 66 (68.8%) were females, and 30 (31.3%) were males, with a mean age of 29.42 years. Rural residents constituted 51 (53.1%) participants. The majority of the patients belonged to lower socioeconomic groups (59.4%). Non-prescription use was reported by 62 (64.6%) patients, most commonly recommended by pharmacists (32, 51.6%). Clobetasol propionate was the most frequently used steroid by 43 (44.8%) patients, and 45 (46.9%) patients had used other superpotent corticosteroids. The mean duration of use of topical agents was 13.65 months. Common indications for usage included melasma (39, 40.6%), tinea (29, 30.2%), and acne (24, 25%). The most frequent adverse effects were hypopigmentation (84, 87.5%), cutaneous atrophy (84, 87.5%), hypertrichosis (69, 71.9%), acneiform eruptions (61, 63.5%), and telangiectasia (61, 63.5%). A large proportion of patients (92, 95.8%) were unaware of the contents of the creams, and 94 participants (97.9%) did not read product leaflets. The overall total economic burden was INR 1,72,659 (USD 1885), with marked individual financial expenditure.
conclusionFacial misuse of TCS is highly prevalent in Western Uttar Pradesh, largely driven by over-the-counter (OTC) availability, pharmacist recommendation, prescription by non-registered practitioners, and poor awareness. There is an urgent need for stricter regulation of potent steroids, banning irrational fixed-dose combinations, and large-scale public and pharmacist education to prevent further morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.